Pieris Pharmaceuticals, INC 10-Q quarterly reports

Palvella Therapeutics reports substantial progress in its QTORIN rapamycin development for rare skin diseases, with an NDA submission on track for H2 2026 and a potential 2027 U.S. launch, alongside increased R&D spending.

Palvella Therapeutics reports a significant increase in R&D expenses for Q1 2026, alongside a substantial cash infusion from a recent equity financing.

Palvella Therapeutics, a clinical-stage biopharmaceutical company, reported increased net losses and cash burn in Q3 2025, while successfully completing enrollment for two key clinical trials and expanding its QTORIN rapamycin development program.

Palvella Therapeutics, a clinical-stage biopharmaceutical company, reported increased operating losses in Q2 2025 but maintains sufficient cash to fund operations into the second half of 2027, driven by ongoing clinical trials for rare skin diseases.

Palvella Therapeutics reports a net loss of $8.2 million for Q1 2025, focusing on the clinical development of QTORIN rapamycin for rare genetic skin diseases.

Pieris Pharmaceuticals is set to merge with Palvella Therapeutics, marking a significant strategic shift following a period of restructuring and discontinued research programs.

Pieris Pharmaceuticals reported a net loss for Q2 2024 and announced a merger agreement with Palvella Therapeutics, shifting its strategic focus.

Pieris Pharmaceuticals is discontinuing research and development efforts to focus on partnered immuno-oncology assets and extend its cash runway into 2027.